Related Experiment Video

Updated: May 5, 2026

RNA Interference in Ticks
09:06

RNA Interference in Ticks

Published on: January 20, 2011

18.2K

Pharmacological Agent GW4869 Inhibits Tick-Borne Langat Virus Replication to Affect Extracellular Vesicles Secretion

Md Bayzid1, Biswajit Bhowmick1, Waqas Ahmed1

  • 1Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA.

Viruses
|July 30, 2025
PubMed

Insights

GW4869, an inhibitor of extracellular vesicle (EV) release, significantly reduces Langat Virus (LGTV) replication in tick cells. This study shows GW4869 impacts viral load and EV concentration, suggesting therapeutic potential for tick-borne flavivirus diseases.

Area of Science:

  • Virology
  • Cell Biology
  • Pharmacology

Background:

  • Extracellular vesicles (EVs) play roles in viral infections.
  • GW4869 inhibits EV production and has shown antiviral properties.
  • Mechanisms of GW4869's antiviral effects, particularly against tick-borne flaviviruses, require elucidation.

Purpose of the Study:

  • To investigate how GW4869 interferes with Langat Virus (LGTV) replication in ISE6 tick cells.
  • To determine if GW4869 affects viral load, viral transcripts, and EV production/release.

Main Methods:

  • Treatment of ISE6 tick cells with GW4869 followed by LGTV infection.
  • Assessment of cytotoxicity, viral load, viral transcript levels, and EV concentration.
  • Analysis of GW4869's effect on viral particles and EVs using density gradient fractionation.

Main Results:

  • GW4869 is non-cytotoxic to tick cells and does not directly bind LGTV.
  • GW4869 treatment significantly reduced LGTV replication and viral burden in tick cells.
  • Decreased LGTV transcript levels and EV concentrations were observed in GW4869-treated cells and their derived EVs.
  • GW4869 reduced LGTV loads within EVs and interfered with EV secretion.

Conclusions:

  • GW4869 effectively inhibits LGTV replication in tick cells by affecting viral load and EV release.
  • The drug's mechanism involves interfering with EV secretion rather than direct viral inactivation.
  • GW4869 shows promise as a therapeutic agent for controlling tick-borne flavivirus infections.